Cabaletta Bio Q1 2021 Earnings Report
Key Takeaways
Cabaletta Bio reported the acute safety data from the first cohort in the DesCAARTes™ trial with no dose limiting toxicities or clinically relevant adverse events. They also announced PLA2R-CAART as a new development program and are planning to submit an IND application for MuSK-CAART in the second half of 2021.
Initial safety data from the first low dose cohort of three patients in the DesCAARTes™ clinical trial for DSG3-CAART support the acute safety profile of DSG3-CAART.
PLA2R-CAART announced as a new development program for patients with PLA2R-associated membranous nephropathy with a pre-IND meeting planned for the second half of 2021.
MuSK-CAART Investigational New Drug (IND) application submission planned for the second half of 2021.
Cash, cash equivalents and investments as of March 31, 2021, along with proceeds from sales will enable it to fund its operating plan through at least the fourth quarter of 2022.